NOVO NORDISK A/S |
Market Closed -
Other stock markets
|
After market 20:00:00 | |||
| 126.8 USD | +0.84% |
|
127.3 | +0.36% |
| 04-25 | NOVO NORDISK : JP Morgan gives a Buy rating | ZD |
| 04-25 | Scholz promises support for pharma sector in Germany as Merck invests | RE |
| Sales 2024 * | 287B 41.21B 56.3B | Sales 2025 * | 346B 49.58B 67.73B | Capitalization | 3,955B 567B 775B |
|---|---|---|---|---|---|
| Net income 2024 * | 104B 14.85B 20.29B | Net income 2025 * | 125B 17.9B 24.46B | EV / Sales 2024 * | 13.8 x |
| Net Debt 2024 * | 23.85B 3.42B 4.67B | Net cash position 2025 * | 348M 49.96M 68.25M | EV / Sales 2025 * | 11.4 x |
| P/E ratio 2024 * |
38.4
x | P/E ratio 2025 * |
31.6
x | Employees | 63,845 |
| Yield 2024 * |
1.33% | Yield 2025 * |
1.59% | Free-Float | 71.17% |
More Fundamentals
* Assessed data
More news
Latest transcript on Novo Nordisk A/S
More press releases
More news
| 1 day | +0.36% | ||
| 1 week | +3.37% | ||
| Current month | -1.21% | ||
| 1 month | -1.98% | ||
| 3 months | +17.38% | ||
| 6 months | +33.25% | ||
| Current year | +22.62% |
1 week
122.57
128.76
1 month
121.79130.16
Current year
101.71138.28
1 year
75.56138.28
3 years
36.76138.28
5 years
23.24138.28
10 years
15.45138.28
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 58 | 90-12-31 | |
| Director of Finance/CFO | 53 | 98-12-31 | |
Stephen Gough
CTO | Chief Tech/Sci/R&D Officer | - | 15-09-30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Sylvie Grégoire
BRD | Director/Board Member | 63 | 15-03-18 |
Helge Lund
CHM | Chairman | 61 | 17-03-22 |
Martin MacKay
BRD | Director/Board Member | 68 | 18-02-28 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 1.75% | 9 M€ | -4.31% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-26 | 126.8 | +0.84% | 3,312,457 |
| 24-04-25 | 125.8 | -0.29% | 3,434,352 |
| 24-04-24 | 126.2 | -1.93% | 3,143,089 |
| 24-04-23 | 128.6 | +2.70% | 3,703,606 |
| 24-04-22 | 125.3 | +2.08% | 3,798,340 |
Delayed Quote Nyse, April 26, 2024 at 04:00 pm
More quotes
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
Pharmaceuticals
Calendar
2024-05-02
- Q1 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
886.6
DKK
Average target price
904.2
DKK
Spread / Average Target
+1.99%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +25.83% | 661B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +13.09% | 231B | |
| +5.46% | 200B | |
| -9.61% | 195B | |
| -6.26% | 145B | |
| -11.77% | 144B |
- Stock Market
- Equities
- NOVO B Stock
- NVO Stock
